415 Capital Management – a global leader in medical technology venture capital – announced the launch of its second fund 415 Capital Fund II, with a target of €150 million ($165 million).
This fund will be focused on advancing breakthrough, life-saving medical technologies, especially those addressing cardiovascular and neurovascular diseases – which are the leading causes of death and disability worldwide, and the top drivers of healthcare costs.
A majority of the fund’s target commitments have already been secured from prominent limited partners, including the European Investment Fund (EIF), KfW Capital, Wachstumsfonds Deutschland (established on Universal Investment’s platform and including over 20 institutional investors, among them insurance companies, foundations and asset managers) and several reputable family offices from Europe and North America. And leading physician-innovators have also joined as investors. The final closing of 415 Capital Fund II is anticipated by the end of the first quarter of 2025.
The fund already made investments in two clinical-stage cardiovascular companies, with additional transactions expected to be revealed soon.
In connection with the successful fundraising, 415 Capital also announced the appointments of Azin Parhizgar, PhD, and Ruben Osnabrugge, MD, PhD to its Investment Committee.
KEY QUOTE:
“We are incredibly grateful for the trust our limited partners continue to place in us. Their support highlights the significant clinical impact and value of our portfolio. Since launching our first institutional fund in 2020, we’ve partnered with visionary entrepreneurs who have achieved key clinical, regulatory, and commercial milestones. These successes have generated significant value for our investors while improving patient outcomes globally. With a larger fund and a robust pipeline of high-quality opportunities ahead, we are poised to make an even greater impact on patient care.”
“Azin has been instrumental in building the 415 Capital platform since its inception. Her unique combination of scientific, entrepreneurial, and operational expertise is invaluable to our team. We are also very excited to welcome Ruben to the Investment Committee. Since joining us in 2023, Ruben has leveraged his expertise in cardiac surgery, clinical trials and healthcare economics to drive value across our portfolio.”
- Frederik Groenewegen, Co-Founder and General Partner at 415 Capital
